APA (7th ed.) Citation

Schwedt, T. J., Myers Oakes, T. M., Martinez, J. M., Vargas, B. B., Pandey, H., Pearlman, E. M., . . . Goadsby, P. J. (2024). Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial. Neurology and therapy, 13(1), 85-105. https://doi.org/10.1007/s40120-023-00562-w

Chicago Style (17th ed.) Citation

Schwedt, Todd J., et al. "Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial." Neurology and Therapy 13, no. 1 (2024): 85-105. https://doi.org/10.1007/s40120-023-00562-w.

MLA (9th ed.) Citation

Schwedt, Todd J., et al. "Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial." Neurology and Therapy, vol. 13, no. 1, 2024, pp. 85-105, https://doi.org/10.1007/s40120-023-00562-w.